OTTAVA (J&J MedTech) vs Osso VR
OTTAVA is a capital purchase for a hospital robotic surgery program. FDA granted it De Novo authorization in July 2026 (DEN250068) for ten general surgery procedures, among them cholecystectomy and gastric sleeve, and J&J is starting with select US customers. A program willing to be an early site gets a table-integrated soft-tissue robot.
Osso VR sells to a health system's nurse education team. Its Nursing Series runs individual and collaborative procedural scenarios on off-the-shelf headsets, with prebriefs, debriefs and dashboards in Osso Loop. Price is on request and headsets cost extra. Its randomized trials score simulated and sawbones tasks, and TechCrunch reported Osso financed the UCLA trial of 20 participants.
The two never meet in one purchase decision. One is operating-room capital, the other is headset training software for health systems. For a nurse educator with a training budget, OTTAVA loses: it is a robot sale, and J&J describes Polyphonic as support for OTTAVA surgical teams.
Surgical AI · Reviewed November 1, 2026
OTTAVA (J&J MedTech)
by J&J MedTech
OTTAVA, Johnson & Johnson MedTech's soft-tissue surgical robot (FDA De Novo, July 2026), with its Polyphonic digital layer.
Osso VR
by Osso VR
VR procedural-skills training for healthcare, including nurse and surgical training.
When to pick each one
OTTAVA (J&J MedTech)
- FDA De Novo authorized soft-tissue robot
- Hospital robotic surgery programs, capital sale
- Select US customers first
Osso VR
- Procedural VR training on off-the-shelf headsets
- Nursing series with debriefs and dashboards
- Randomized trials on orthopedic simulation tasks
Score
Each row shows points earned of points available under the published rubric.
OTTAVA (J&J MedTech)
35of 100
Osso VR
48of 100
| Dimension | OTTAVA (J&J MedTech) | Osso VR | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 1.4 | 0 / 1.4 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 0.8 | 0 / 0.8 | 0 |
| Peer-reviewed papers | 0 / 21 | 21 / 21 | -21 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
OTTAVA (J&J MedTech)
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Capital sale. |
Osso VR
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price, pricing is requested through the website. Headsets cost extra. |
Evidence
OTTAVA (J&J MedTech)
FDA decisions
DEN250068 (opens in new tab)De Novo2026-07-21
OTTAVA Robotic Surgical System (applicant Auris Health, Inc.)
Osso VR
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
5 PubMed records name Osso VR.
- The Utility of Virtual Reality in Orthopedic Surgical Training. (opens in new tab)
- Randomized Trial of a Virtual Reality Tool to Teach Surgical Technique for Tibial Shaft Fracture Intramedullary Nailing. (opens in new tab)
- Does Virtual Reality Improve Procedural Completion and Accuracy in an Intramedullary Tibial Nail Procedure? A Randomized Control Trial. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | OTTAVA (J&J MedTech) | Osso VR |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full surgical ai comparison
Surgical video intelligence (Theator), OR analytics (OR Black Box), VR training (Osso VR, FundamentalVR), robotic AI (da Vinci 5 Case Insights). Mostly enterprise capital purchases.